アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - mirtazapine - orodispersible tablet - 45 milligram(s) - other antidepressants; mirtazapine

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

mylan institutional inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the effectiveness of mirtazapin

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of mirtazapine in hospitalized depress

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - mirtazapine - orodispersible tablet - 30mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - mirtazapine - orodispersible tablet - 45mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - mirtazapine - orodispersible tablet - 15mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - mirtazapine - orodispersible tablet - 45mg

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the effectiveness of mirtazapine in hospitalized dep

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

organon pharma (ireland) limited - mirtazapine - orodispersible tablet - 15 milligram(s) - other antidepressants; mirtazapine

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

organon pharma (ireland) limited - mirtazapine - orodispersible tablet - 30 milligram(s) - other antidepressants; mirtazapine